ORIC Pharmaceuticals reported mixed clinical signals for its oral targeted therapy in lung cancer: the agent showed encouraging activity in certain first- and second-line settings for patients with the intended genetic alteration but was discontinued for HER2-mutant tumors after insufficient activity. The company will prioritize contexts where the drug demonstrated measurable benefit and de-emphasize development for HER2-driven disease. Investors and competitors will watch how ORIC reallocates resources to maximize clinical and commercial potential.